The Origin: 20 Years of Multiplex PCR Leadership
From one breakthrough
From one breakthrough
to a global movement.
For over two decades, Seegene has led the evolution of multiplex PCR —
transforming innovation into accessibility and setting the foundation for a world free from disease.
transforming innovation into accessibility and setting the foundation for a world free from disease.
Milestones of Innovation and Global Impact
From the first multiplex PCR assay to a fully automated platform shared across continents,
our journey is a story of continual reinvention —
advancing diagnostics, expanding access, and connecting scientists worldwide.
our journey is a story of continual reinvention —
advancing diagnostics, expanding access, and connecting scientists worldwide.
-
2000
-
Sep, 2000 Established Seegene, Inc. and Institute of Life science at Ehwa Women's University, Seoul, Korea
-
2010
-
Sep, 2010 Initial Public Offering on the KOSDAQ
-
2020
-
Dec, 2020 Exceeded 1 trillion won in 2020 annual sales
-
-
2023
-
June, 2023
Springer Nature :
Partnership Agreement for Technology-Sharing Initiative -
Sep, 2023
Open Innovation Program
Global Competition Launch
-
2024
-
Jan, 2024
Microsoft :
Strategic Collaboration -
May, 2024
Strategic Alliance Agreement with Springer Nature
-
Oct, 2024
Seegene-Microsoft-Springer Nature
Partner Roundtable
-
2025
-
Mar, 2025
Microsoft AI Tour Seoul
Announcement of Automated Diagnostic Reagent Development Solution -
Apr, 2025 Establishment of NewCo (Israel)
-
May, 2025 Establishment of NewCo (Spain)
-
Jun, 2025 Establishment of Seegene Technologies (California, USA)
-
Oct, 2025 Launch of Technology-Sharing Initiative with NewCo (Spain)
-
2026
-
2026 Next Phase of the Technology-Sharing Initiative with NewCo(Israel)
-
2026 Launch of Technology-Sharing Initiative with NewCo (Spain)
-
The Future:
A Connected Global PCR Ecosystem
Seegene Technology envisions a future where every country holds diagnostic sovereignty.
Through our syndromic PCR, automation, and Technology-Sharing model,
we aim to build a world where innovation flows freely — enabling rapid, localized responses to every emerging disease.
Through our syndromic PCR, automation, and Technology-Sharing model,
we aim to build a world where innovation flows freely — enabling rapid, localized responses to every emerging disease.